HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Brentuximab vedotin in the treatment of a patient with refractory Hodgkin disease and Proteus syndrome - a case report and discussion.

Abstract
Treatment of patients with refractory Hodgkin lymphoma is a significant issue. We report a patient with Proteus syndrome and relapsed Hodgkin lymphoma, whose remission was finally achieved after brentuximab vedotin therapy, allowing her to receive a haploidentical stem cell transplant. The possible relationship between both disorders was discussed.
AuthorsNatalia Myakova, Nadezhda Smirnova, Dmitry Evstratov, Yulia Abugova, Dmitry Balashov, Yulia Diakonova, Dmitry Konovalov, Yulia Skvortsova, Alexey Maschan
JournalClinical case reports (Clin Case Rep) Vol. 3 Issue 7 Pg. 646-9 (Jul 2015) ISSN: 2050-0904 [Print] England
PMID26273462 (Publication Type: Case Reports)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: